International Business News - MYGN http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Among the stock activity stories for Tuesday, Nov. 4, from AP Financial News: SALT LAKE CITY (AP)--Shares of Myriad Genetics Inc. climbed to a seven-year high Tuesday after the company posted strong third-quarter results, swinging to a profit due to gains in molecular diagnostics sales. http://www.ibtimes.com/articles/20081104/movers-roundup-myriad-genetics-health-net.htm Tue, 04 Nov 2008 18:01:44 EST Shares of Myriad Genetics Inc. climbed to a seven-year high Tuesday after the company posted strong third-quarter results, swinging to a profit due to gains in molecular diagnostics sales. http://www.ibtimes.com/articles/20081104/myriad-genetics-hits-high-after-solid-3q-results.htm Tue, 04 Nov 2008 16:19:41 EST Among the earnings stories for Tuesday, Nov. 4, from AP Financial News: DALLAS (AP)--Denbury Resources Inc. said third-quarter profit more than doubled due in part to higher prices for crude and natural gas. http://www.ibtimes.com/articles/20081104/earnings-roundup-denbury-louisiana-pacific.htm Tue, 04 Nov 2008 14:41:35 EST Myriad Genetics Inc. said Tuesday it swung to a profit in the fiscal first quarter due to surging sales in its molecular diagnostics business, which includes tests to assess patients' risk of getting cancers of the breast, ovaries or colon. http://www.ibtimes.com/articles/20081104/molecular-testing-sales-lift-myriad-to-1q-profit.htm Tue, 04 Nov 2008 12:55:20 EST Biotechnology company Myriad Genetics Inc. said Monday it will split into two public companies to create better growth opportunities for its research and drug development business and its molecular diagnostics business. http://www.ibtimes.com/articles/20081020/myriad-genetics-to-split-into-2-companies.htm Mon, 20 Oct 2008 18:33:52 EDT Among the stock activity stories for Tuesday, Oct. 7, from AP Financial News: NEW YORK (AP)--Shares of Bank of America Corp. fell sharply, a day after the banking giant reported worse-than-expected earnings, announced plans to raise $10 billion in capital and slashed its dividend in half. http://www.ibtimes.com/articles/20081007/movers-roundup-bank-of-america-ibm.htm Tue, 07 Oct 2008 19:45:41 EDT Shares of Myriad Genetics Inc. slipped Tuesday, even after the biotechnology company said it licensed drug analysis technology from Saladax Biomedical Inc. http://www.ibtimes.com/articles/20081007/myriad-up-after-licensing-chemo-dosing-technology.htm Tue, 07 Oct 2008 19:41:33 EDT Myriad Genetics Inc. said Wednesday an early-stage study of its experimental HIV drug Vivecon shows the drug has a favorable safety profile, with no patients experiencing serious side effects. http://www.ibtimes.com/articles/20080917/myriad-study-hiv-drug-has-good-safety-profile.htm Wed, 17 Sep 2008 13:14:42 EDT An RBC Capital Markets analyst said Friday he expects Myriad Genetics Inc. to spin off its pharmaceutical business next year, and said its molecular diagnostics business would be worth $75 per share as a standalone company. http://www.ibtimes.com/articles/20080912/ahead-of-the-bell-myriad-genetics.htm Fri, 12 Sep 2008 09:27:06 EDT Myriad Genetics Inc. said Thursday its board is looking over the results of a strategic review, and expects to make a decision by the end of 2008. Myriad said in August that it would evaluate several alternatives to improve shareholder value. One of those options involved spinning off the company's core molecular diagnostics business and separating the less profitable pharmaceutical unit. http://www.ibtimes.com/articles/20080911/myriad-genetics-board-looks-at-strategic-options.htm Thu, 11 Sep 2008 07:31:21 EDT Among the stock activity stories for Tuesday, Aug. 19, from AP Financial News: NEW YORK (AP)--Marshall & Ilsley Corp. shares fell Tuesday as Wall Street pulled back on discouraging government data on inflation and the housing sector. http://www.ibtimes.com/articles/20080819/movers-roundup-marshall-ilsley-bjs-wholesale.htm Tue, 19 Aug 2008 14:31:53 EDT Myriad Genetics Inc.'s fiscal fourth-quarter results generally met expectations, but the biotechnology company's stock declined in Tuesday trading. Myriad swung to a profit for the quarter. Most of its revenue came from a $100 million payment from H. Lundbeck A/S, a Danish pharmaceutical company that paid to license Myriad's Alzheimer's disease drug candidate Flurizan. Revenue from the molecular diagnostics business grew 53 percent, to $64.7 million. http://www.ibtimes.com/articles/20080819/myriad-genetics-slips-following-4q-results.htm Tue, 19 Aug 2008 19:19:24 EDT Biotechnology company Myriad Genetics Inc. said Tuesday it swung to a profit in its fiscal fourth quarter, boosted by a large payment for Flurizan, a since-canceled Alzheimer's disease drug candidate. http://www.ibtimes.com/articles/20080819/flurizan-payment-pushes-myriad-to-fiscal-4q-profit.htm Tue, 19 Aug 2008 07:26:14 EDT Shares of Myriad Genetics bounced back Tuesday after a tumble the day before on the biotechnology company's announcement that it will stop development of the Alzheimer's disease treatment Flurizan. http://www.ibtimes.com/articles/20080701/a-second-look-myriad-genetics.htm Tue, 01 Jul 2008 12:25:52 EDT Shares of Myriad Genetics Inc. fell Monday morning after the company said it will end development of Alzheimer's disease drug candidate Flurizan, after it proved no better than placebo in a late-stage trial. http://www.ibtimes.com/articles/20080630/out-of-the-gate-myriad-skids-on-flurizan-failure.htm Mon, 30 Jun 2008 11:52:49 EDT H&R Block Inc. rose in premarket trading Monday after the tax preparer said it swung to a fiscal fourth-quarter profit, helped by a record-setting tax season and the sale of its troubled mortgage unit. http://www.ibtimes.com/articles/20080630/premarket-movers-h-r-block-rises-myriad-falls.htm Mon, 30 Jun 2008 08:57:14 EDT Biotechnology company Myriad Genetics Inc. said Monday it will end development of Alzheimer's treatment candidate Flurizan after the drug failed to meet goals of an 18-month, late-stage trial. http://www.ibtimes.com/articles/20080630/myriad-genetics-ends-development-of-flurizan.htm Mon, 30 Jun 2008 07:59:16 EDT Shares of Irish drug maker Elan Corp. PLC hit a six-year high Monday as one analyst predicted success for its Alzheimer's disease treatment bapineuzumab, and another voiced skepticism about a rival drug. http://www.ibtimes.com/articles/20080623/adrs-in-focus-elan-climbs-to-6-year-high.htm Mon, 23 Jun 2008 12:32:40 EDT Among the stock activity stories for Wednesday, May 28, from AP Financial News: NEW YORK (AP)--Shares of Polo Ralph Lauren Corp. rose on Wednesday, after the apparel maker reported better-than-expected fourth-quarter earnings as sales jumped. http://www.ibtimes.com/articles/20080528/movers-roundup-polo-ralph-lauren-brunswick.htm Wed, 28 May 2008 18:34:40 EDT Shares of biotechnology company Myriad Genetics Inc. fell Wednesday on continued concern that the company's Alzheimer's disease drug candidate Flurizan could miss its goal in a late-stage study. http://www.ibtimes.com/articles/20080528/myriad-genetics-falls-on-drug-program-concerns.htm Wed, 28 May 2008 17:44:50 EDT